<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938792</url>
  </required_header>
  <id_info>
    <org_study_id>B7841005</org_study_id>
    <secondary_id>2018-003660-31</secondary_id>
    <nct_id>NCT03938792</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B</brief_title>
  <official_title>An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity &lt;1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity â‰¤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage&#xD;
      and/or a major contribution to patient care in comparison to current methods of treatment for&#xD;
      hemophilia A or B because it works differently than factor replacement products and will work&#xD;
      in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC)&#xD;
      administration provides for treatment options in the absence of reliable vascular access,&#xD;
      increased convenience and may enable better compliance. Combined, these qualities should&#xD;
      result in a reduction of bleeding episodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">August 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a one way Cross-Over Prevention study with 1 Arm that has No masking.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized bleeding rate (ABR) of treated bleeding events</measure>
    <time_frame>Through Observational Phase (6months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
    <description>Derived for each subject for each treatment period by using the following formula: ABR = number of bleeds requiring treatments/ (days on treatment period / 365.25)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of thrombotic events</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti drug antibody [ADA] against PF-06741086</measure>
    <time_frame>Throughout Active Treatment Phase (12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant persistent neutralizing antibody [NAb] against PF-06741086</measure>
    <time_frame>Throughout Active Treatment Phase (12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of injection site reaction</measure>
    <time_frame>Throughout Active Treatment Phase (12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes from baseline in physical exam</measure>
    <time_frame>From Baseline through Observation and Active Treatment (approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant laboratory value abnormalities</measure>
    <time_frame>From Screening through Observation and Active Treatment (approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe hypersensitivity and anaphylactic reactions</measure>
    <time_frame>From Screening through Observational and Active Treatment (approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>From screening through Observation and Active treatment (approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes from baseline in vital signs</measure>
    <time_frame>From Baseline through Observation and Active Treatment (approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of thromboticangiopathy</measure>
    <time_frame>Throughout Active Treatment Phase (12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of intravascular coagulation/consumption coagulopathy</measure>
    <time_frame>Throughout Active Treatment Phase (12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total coagulation factor and/or bypass product consumption</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
    <description>The Total Factor/bypass product consumed per participant as measured in total IU and IU/kg per month and per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of joint bleeds</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous bleeds</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of target joint bleeds</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of total bleeds (treated and untreated)</measure>
    <time_frame>Through Observational and Active Treatment Phases (18 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with no bleeding episodes</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Hemophilia Joint Health Score (HJHS)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in (Haemophilia Adult Quality of Life Questionnaire (Haem-A-QoL)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hemophilia Adult Activities List (HAL)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hemophilia Pediatric Activities List (PedHAL)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change - Hemophilia (PGIC-H)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L)</measure>
    <time_frame>Through Observational Phase (6 months) and Active Treatment Phase (12 months) for total of approximately 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>PF-06741086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.</description>
    <arm_group_label>PF-06741086</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Participants with a diagnosis of severe hemophilia A or moderately severe to severe&#xD;
             hemophilia B with a minimum weight of 35 kg at screening.&#xD;
&#xD;
          -  Participant or legally authorized representative, or participant's caregiver capable&#xD;
             of giving signed informed consent (or minor assent, when applicable).&#xD;
&#xD;
        Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following&#xD;
        criteria:&#xD;
&#xD;
          -  No detectable or documented history of inhibitors&#xD;
&#xD;
          -  Participants on FVIII/FIX routine prophylaxis who have demonstrated at least 80%&#xD;
             compliance with scheduled prophylaxis regimen during 6 months prior to enrollment and&#xD;
             are willing to continue to receive routine prophylaxis treatment with FVIII/FIX&#xD;
             replacement during the Observational Phase.&#xD;
&#xD;
          -  Participants with on-demand treatment regimen with â‰¥6 acute bleeding episodes&#xD;
             (spontaneous or traumatic) that required coagulation factor infusion during the 6&#xD;
             months period prior to enrollment and willing to continue to receive on demand&#xD;
             treatment during the Observational Phase.&#xD;
&#xD;
        Participants who are enrolled into the Inhibitor Cohort must also meet the following&#xD;
        criteria:&#xD;
&#xD;
          -  Documentation of current high titer inhibitor (â‰¥5 BU/mL) or current low titer&#xD;
             inhibitor (&lt;5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX&#xD;
             recovery &lt;60% of expected within previous 6 months prior to enrolment into the&#xD;
             Observational Phase&#xD;
&#xD;
          -  Hemophilia A participants with on-demand treatment regimen with â‰¥6 bleeding episodes&#xD;
             or hemophilia B participants with â‰¥4 bleeding episodes (spontaneous or traumatic)&#xD;
             necessitating treatment with bypass factor during the 6 months prior to Enrollment&#xD;
             into Observational Phase and willing to continue to receive on-demand treatment during&#xD;
             the Observational Phase.&#xD;
&#xD;
          -  Participants who have documented inhibitors while on factor-replacement therapy but&#xD;
             who do not meet the quantitative inhibitor criteria described in the prior bullet at&#xD;
             the time of Screening (eg, participant with a previously documented high-titer&#xD;
             inhibitor (â‰¥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX&#xD;
             replacement) may be considered for eligibility on a case-by-case basis with prior&#xD;
             agreement from the Pfizer Medical Monitor&#xD;
&#xD;
          -  Participants who meet the bleeding criteria noted above and who are on routine&#xD;
             prophylaxis (defined as treatment by IV injection of bypass factor to prevent&#xD;
             bleeding) and have demonstrated at least 80% compliance with scheduled prophylaxis&#xD;
             regimen during the 6 months prior to enrollment, may be considered for eligibility on&#xD;
             a case-by-case basis with discussion and agreement from the Pfizer medical monitor.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Previous or current treatment for and/or history of coronary artery diseases, venous&#xD;
             or arterial thrombosis or ischemic disease&#xD;
&#xD;
          -  Known planned surgical procedure during the planned study period.&#xD;
&#xD;
          -  Known hemostatic defect other than hemophilia A or B.&#xD;
&#xD;
          -  Abnormal renal or hepatic function&#xD;
&#xD;
          -  Current unstable liver or biliary disease&#xD;
&#xD;
          -  Abnormal hematologic parameters&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             may increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator,&#xD;
&#xD;
          -  Current routine prophylaxis with bypassing agent or non-coagulation non-factor-&#xD;
             replacement therapy, or any previous treatment with a gene therapy product for&#xD;
             treatment of hemophilia (participants treated with prophylaxis using bypassing agents&#xD;
             or who had prior treatment with non-factor products may be considered on a&#xD;
             case-by-case basis).&#xD;
&#xD;
          -  Regular, concomitant therapy with immunomodulatory drugs&#xD;
&#xD;
             - Ongoing or planned use of immune tolerance induction during the Observational Phase&#xD;
             or Active Treatment Phase, or prophylaxis with FVIII or FIX replacement at any time&#xD;
             after initiation of treatment with study intervention during the Active Treatment&#xD;
             Phase&#xD;
&#xD;
          -  Previous exposure to PF 06741086 during participation in studies B7841002 and&#xD;
             B7841003.&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) or investigational&#xD;
             vaccines within 30 days (or as determined by local requirements) or 5 half-lives prior&#xD;
             to study entry and/or during study participation.&#xD;
&#xD;
          -  CD4 cell count â‰¤200/uL if human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Screening ECG that demonstrates clinically relevant abnormalities that may affect&#xD;
             participant safety or interpretation of study results.&#xD;
&#xD;
          -  Individuals with hypersensitivity or an allergic reaction to hamster protein or other&#xD;
             components of the study intervention.&#xD;
&#xD;
          -  Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             participants who are Pfizer employees, including their family members, directly&#xD;
             involved in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USF Health Morsani Center For Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health HTC</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment ''Georgi Stranski'' EAD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Prof.Dr. Stoyan Kirkovich&quot;</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre - Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>306113</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU HÃ´tel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-UniversitÃ¤t, Medizinische Klinik II,</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Pvt, Ltd</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahyadri Clinical Research and Development Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahyadri Super Speciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil NADU</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Roma &quot;Sapienza&quot;-Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital - Transfusion Medicine</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Children's Medical Center</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>183-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daejeon Eulji Medical Center Eulji University</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Multidisciplinario para el Desarrollo Especializado de la Inv. ClÃ­nica en YucatÃ¡n, S.C.P.</name>
      <address>
        <city>MÃ©rida</city>
        <state>YucatÃ¡n</state>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sultan Qaboos University Hospital</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;Samara State Medical University&quot; of MoH of Russia</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Mother and Child healthcare &quot;Dr Vukan Cupic&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall dÂ´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del RocÃ­o</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ChangHua Christian Hospital</name>
      <address>
        <city>Changhua City</city>
        <state>Changhua County</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi University Health Research and Practice Center Gazi Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <zip>07060</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Sahinbey Research and Training Hospital</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Oncology Institute</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erciyes University Medical Faculty</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ondokuz MayÄ±s University Medical Faculty</name>
      <address>
        <city>Samsun</city>
        <zip>55280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Oman</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Ireland</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7841005</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII</keyword>
  <keyword>Factor IX</keyword>
  <keyword>Inhibitors</keyword>
  <keyword>Anti-Tissue Factor Pathway Inhibitor (TFPI)</keyword>
  <keyword>Subcutaneous (sc)</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>On-Demand</keyword>
  <keyword>BASIS</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>SC</keyword>
  <keyword>Subcutaneous</keyword>
  <keyword>Injection</keyword>
  <keyword>On demand</keyword>
  <keyword>aTFPI</keyword>
  <keyword>Anti-TFPI</keyword>
  <keyword>Severe hemophilia</keyword>
  <keyword>Severe bleeding</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>PF-06741086</keyword>
  <keyword>PF 06741086</keyword>
  <keyword>Marstacimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

